唑来膦酸联合碳酸钙d3治疗骨质疏松症的临床研究.pdfVIP

现代药物与临床 Drugs Clinic 第 30 卷 第 2 期 2015 年 2 月 ·203 · 唑来膦酸联合碳酸钙 D3 治疗骨质疏松症的临床研究 郭丙杰，张东洋，李少华 郑州市第九人民医院，河南 郑州 450053 摘 要：目的 探讨唑来膦酸联合碳酸钙 D3 治疗骨质疏松症的临床疗效。方法 2010 年 1 月－2013 年 9 月郑州市第九人 民医院收治的骨质疏松症患者 120 例，随机分为对照组和治疗组，每组 60 例。对照组口服碳酸钙 D3 片，1 片/次，2 次/d 。 治疗组在对照组基础上静脉滴注唑来膦酸注射液（5 mg 以 100 mL 生理盐水稀释），静脉滴注时间大于 15 min，1 次/年。两 组均连续治疗 1 年。观察两组的临床疗效，同时比较两组治疗前后骨密度（BMD ）值，VAS 评分，血钙、磷和碱性磷酸酶 （AKP ）变化。结果 治疗后，对照组和治疗组的总有效率分别为 65.0%、96.7%，两组比较差异有统计学意义（P ＜0.05 ）。 治疗后，治疗组患者 L1～4 BMD 、血钙均较治疗前显著升高，AKP 、VAS 评分显著降低，同组治疗前后差异有统计学意义 （P ＜0.05、0.01 ）；且治疗组的改善程度优于对照组，两组比较差异有统计学意义（P ＜0.05 ）。结论 唑来膦酸联合碳酸钙 D3 治疗骨质疏松症具有较好的临床疗效，可以缓解患者疼痛，改善和维持 BMD 水平，且安全性高，值得临床推广应用。 关键词：唑来膦酸注射液；碳酸钙D3 ；骨质疏松症；骨密度；VAS 评分；碱性磷酸酶 中图分类号：R977 文献标志码：A 文章编号：1674 - 5515(2015)02 - 0203 - 04 DOI:10.7501/j.issn.1674-5515.2015.02.021 Clinical study on zoledronic acid combined with calcium carbonate D3 in treatment of osteoporosis GUO Bing-jie, ZHANG Dong-yang, LI Shao-hua Ninth People’s Hospital of Zhengzhou City, Zhengzhou 450053, China Abstract: Objective To evaluate the clinical efficacy of zoledronic acid combined with calcium carbonate D3 in treatment of osteoporosis. Methods The patients with osteoporosis (120 cases) of Ninth People’s Hospital of Zhengzhou City from January 2010 to September 2013 were randomly divided into control and treatment groups, and each group had 60 cases. The patients in the control group were po administered with Calcium Carbonate D3 Tablets, 1 tablet/time, twice daily. The patients in the control group were iv administered with Zoledronic Acid Injection (5 mg diluted with 100 mL physiological saline) more than 15 min, 1 time/year. The patients in two groups were treated for one year. After the treatment, the efficacy was evaluated, and the changes of BMD, VAS score, blood calcium, phosp